Secondary Prevention Therapies for AMI Part 2: Thrombin Receptor Antagonists - Ori Ben-Yehuda, MD

↳ This is a section part of Moment: CRT 2015 Coronary - The Thrombin Inhibitors Great Debate: Bivailrudin vs. Heparin

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$5.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Secondary Prevention Therapies for AMI Part 2: Thrombin Receptor Antagonists presented by Ori Ben-Yehuda, MD at CRT 2015

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$5.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Interventional Cardiologists
  • Interventional Fellows

Session Name: The Thrombin Inhibitors Great Debate: Bivailrudin vs. Heparin

Track: Coronary

Learning Objectives

  • Update in advances in ACS & AMI Management

Other Components in this Moment

Overview
Bivalirudin Superior to Heparin for ACS Patients - Gregg W. Stone, MD
Heparin Should be the First-line Therapy for Patients with ACS/AMI - Cindy L. Grines, MD
Secondary Prevention Therapies for AMI Part I: Aspirin and ADP Antagonists - Deepak Bhatt, MD
Secondary Prevention Therapies for AMI Part 2: Thrombin Receptor Antagonists - Ori Ben-Yehuda, MD
Loading Simple Education